KURA - Kura Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5999.52M
Enterprise Value 3605.19M
Trailing P/E N/A
Forward P/E 1-9.12
PEG Ratio (5 yr expected) 1-0.50
Price/Sales (ttm)N/A
Price/Book (mrq)4.00
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 2.29
52-Week Change 3-11.27%
S&P500 52-Week Change 34.59%
52 Week High 321.15
52 Week Low 36.35
50-Day Moving Average 317.15
200-Day Moving Average 313.20

Share Statistics

Avg Vol (3 month) 3752.69k
Avg Vol (10 day) 3334.54k
Shares Outstanding 555.9M
Float 40.46M
% Held by Insiders 113.02%
% Held by Institutions 173.71%
Shares Short (Jun. 14, 2020) 42.83M
Short Ratio (Jun. 14, 2020) 45.15
Short % of Float (Jun. 14, 2020) 46.06%
Short % of Shares Outstanding (Jun. 14, 2020) 45.07%
Shares Short (prior month May 14, 2020) 42.8M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-22.95%
Return on Equity (ttm)-38.78%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
Net Income Avi to Common (ttm)-68.41M
Diluted EPS (ttm)-1.56
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)216.94M
Total Cash Per Share (mrq)4.77
Total Debt (mrq)9.72M
Total Debt/Equity (mrq)4.78
Current Ratio (mrq)15.19
Book Value Per Share (mrq)4.47

Cash Flow Statement

Operating Cash Flow (ttm)-60.33M
Levered Free Cash Flow (ttm)-36.69M